Keyphrases
Lymphoma Patients
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Prognostic Impact
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Myeloid Differentiation Factor 88 (MyD88)
100%
Overall Survival
66%
Cell-like
33%
Progression-free Survival
33%
Mutation Status
33%
Non-germinal Centre
33%
Prednisone
16%
Relapsed or Refractory
16%
Pretransplant
16%
Newly Diagnosed
16%
Chemotherapy
16%
Poor Prognosis
16%
Disease Relapse
16%
Prognostic Factors
16%
Initial Diagnosis
16%
Salvage Therapy
16%
Activated B Cells
16%
Cell of Origin
16%
Poor Prognostic Factors
16%
International Prognostic Index
16%
Prognostic Score
16%
Cyclophosphamide
16%
High-dose Chemotherapy
16%
Transplant Outcomes
16%
First-line Chemotherapy
16%
Molecular Subtypes
16%
Refractory Diffuse Large B-cell Lymphoma
16%
Activated B-cell Lymphoma
16%
Origin Identification
16%
Oncovin
16%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Autologous Stem Cell Transplantation
100%
Myeloid Differentiation Factor 88
100%
Overall Survival
66%
Transplantation
50%
Progression Free Survival
33%
Prognostic Factor
33%
Salvage Therapy
16%
International Prognostic Index
16%
Cyclophosphamide
16%
Prednisone
16%
High Dose Chemotherapy
16%
First-Line Chemotherapy
16%
Vincristine Sulfate
16%
Diseases
16%
Immunology and Microbiology
B Cell
100%
Autologous Stem Cell Transplantation
100%
Overall Survival
66%
Progression Free Survival
33%
Drug Megadose
16%
Prednisone
16%
Cyclophosphamide
16%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Autologous Stem Cell Transplantation
100%
Overall Survival
66%
Progression Free Survival
33%
Drug Megadose
16%
Cyclophosphamide
16%
Prednisone
16%